ALDX - Aldeyra Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
8.20
+0.49 (+6.36%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close7.71
Open7.71
Bid7.80 x 800
Ask8.19 x 1000
Day's Range7.70 - 8.23
52 Week Range6.75 - 16.70
Volume242,679
Avg. Volume675,295
Market Cap224.642M
Beta (3Y Monthly)1.17
PE Ratio (TTM)N/A
EPS (TTM)-1.79
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.88
Trade prices are not sourced from all markets
  • PR Newswire15 days ago

    Aldeyra Therapeutics Announces Presentation of Phase 2b Dry Eye Disease Results at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

    Reproxalap is a novel immune-modulating RASP (Reactive Aldehyde Species) inhibitor in late-stage development for the treatment of dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson Syndrome. Results from a Phase 2b clinical trial completed in 2018 demonstrated that reproxalap was statistically superior to vehicle across multiple dry eye disease symptoms and signs. The RENEW adaptive Phase 3 clinical trial of topical ocular reproxalap for the treatment of dry eye disease initiated on April 1, 2019.

  • PR Newswire22 days ago

    Aldeyra Therapeutics Announces First Patient Enrolled in the RENEW Phase 3 Clinical Trial for Dry Eye Disease

    LEXINGTON, Mass., April 2, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced enrollment of the first patient into the RENEW Phase 3 clinical trial of topical ocular reproxalap for the treatment of dry eye disease. The RENEW Trial is a two-part, multi-center, randomized, double-masked, parallel-group, vehicle-controlled, adaptive Phase 3 clinical trial evaluating the efficacy of reproxalap ophthalmic solution (0.25%) vs. vehicle in 400 patients with moderate-to-severe dry eye disease.  Results from the first part of the trial will confirm the dosing regimen and sample size for the second part.  The co-primary endpoints of the trial will be ocular dryness and fluorescein nasal region ocular staining in pre-specified moderate to severe patient subsets analyzed over twelve weeks of therapy using Mixed effects Model Repeated Measures (MMRM).

  • Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge
    Zacks27 days ago

    Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge

    Aldeyra (ALDX) announced positive top-line data from a phase III study on pipeline product, reproxalap topical ophthalmic solution in patients with allergic conjunctivitis.

  • TheStreet.com28 days ago

    Future Brightens for 2 Small Biotech Stocks

    The biotech sector got off to a quick start in 2019 but largely has been range-bound here in March -- not that things have not been exciting. Small-cap concerns in the sector also have become more volatile in the last few trading sessions.

  • Here's Why Aldeyra Therapeutics Stock Soared as Much as 79.1% Today
    Motley Fool28 days ago

    Here's Why Aldeyra Therapeutics Stock Soared as Much as 79.1% Today

    The small-cap pharma announced positive results from a phase 3 trial.

  • Aldeyra stock jumps 50 percent after eye allergy trial success
    American City Business Journals28 days ago

    Aldeyra stock jumps 50 percent after eye allergy trial success

    Quiet local biotech Aldeyra Therapeutics made some noise Tuesday, reporting that its first treatment for eye allergies succeeded in a late-stage trial.

  • Reuters29 days ago

    Aldeyra's eye drug meets main goal in late-stage study, shares surge

    The study tested two doses of the drug in 318 patients with seasonal allergic conjunctivitis, an allergic reaction to substances such as pollen or spores causing eye inflammation. Both concentrations of reproxalap exhibited an anti-inflammatory profile distinct from standard-of-care and support a different mechanism of action for the treatment of allergic conjunctivitis, the company said. The results suggest the potential of reproxalap being used to complement existing therapy, Aldeyra Chief Medical Officer David Clark said in a statement.

  • Should Aldeyra Therapeutics (NASDAQ:ALDX) Be Disappointed With Their 68% Profit?
    Simply Wall St.29 days ago

    Should Aldeyra Therapeutics (NASDAQ:ALDX) Be Disappointed With Their 68% Profit?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! It's been a soft week for Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)Read More...

  • MarketWatch29 days ago

    Alderya Therapeutics stock soars after conjunctivitis treatment trial meets key endpoints

    Shares of Aldeyra Therapeutics Inc. shot up 56% toward a 5-month high in premarket trade Tuesday, a day after closing at a 7-month low, after a phase 3 trial of the biotechnology company's allergic conjunctivitis treatment met its primary and secondary endpoints. Trading volume topped 440,000 shares, already more than the full-day average of about 310,000 shares. Aldeyra said it plans to meet with regulatory authorities in the second half of 2019 to discuss the results and remaining clinical requirements for potential submission of a new drug application (NDA) to the Food and Drug Administration. Separately, the company said it entered into a loan and security agreement with Hercules Capital Inc. that provides up to $60 million in financing. "The ALLEVIATE [trial] results suggest the potential of topical ocular reproxalap as a novel, safe, and effective therapeutic option that could be used to complement existing therapy before resorting to corticosteroids, which can lead to serious ocular toxicity," said Aldeyra Chief Medical Officer David Clark. The stock has lost 14.5% over the past 12 months while the iShares Nasdaq Biotechnology ETF has edged up 0.2% and the S&P 500 has gained 5.3%.

  • PR Newswire29 days ago

    Aldeyra Therapeutics Announces Positive Top-Line Results from the Phase 3 ALLEVIATE Trial in Patients with Allergic Conjunctivitis

    LEXINGTON, Mass., March 26, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced positive results from the Phase 3 ALLEVIATE Trial of 0.25% and 0.5% reproxalap topical ophthalmic solution in patients with allergic conjunctivitis. The clinical trial met the primary endpoint and the key secondary endpoint for both concentrations of reproxalap. "We are thrilled to announce positive results from ALLEVIATE, our first completed Phase 3 clinical trial," commented Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra.

  • PR Newswire29 days ago

    Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Top-Line Results from the Phase 3 ALLEVIATE Trial in Allergic Conjunctivitis

    LEXINGTON, Mass. , March 25, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve ...

  • Options Traders Expect Huge Moves in Aldeyra (ALDX) Stock
    Zackslast month

    Options Traders Expect Huge Moves in Aldeyra (ALDX) Stock

    Aldeyra (ALDX) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of ALDX earnings conference call or presentation 8-Mar-19 1:00pm GMT

    Q4 2018 Aldeyra Therapeutics Inc Earnings Call

  • Aldeyra Therapeutics Inc (ALDX) Q4 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Aldeyra Therapeutics Inc (ALDX) Q4 2018 Earnings Conference Call Transcript

    ALDX earnings call for the period ending December 31, 2018.

  • PR Newswire2 months ago

    Aldeyra Therapeutics Announces Year-End 2018 Financial Results

    - Results from the ALLEVIATE Phase 3 Clinical Trial in Allergic Conjunctivitis Expected in Early 2019 - The RENEW Adaptive Phase 3 Clinical Trial in Dry Eye Disease Expected to Begin in First Half of 2019 ...

  • PR Newswire2 months ago

    Aldeyra Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Friday, March 8, 2019

    LEXINGTON, Mass. , March 1, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve ...

  • PR Newswire2 months ago

    Aldeyra Therapeutics Provides Update on Ophthalmic Programs at 2019 Research & Development Day

    LEXINGTON, Mass., Feb. 28, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today updated progress on ophthalmic programs at a 2019 Research & Development Day in New York City. Presentations were given by members of the Aldeyra executive team along with Dean Eliott, M.D., the Stelios Evangelos Gragoudas Professor of Ophthalmology at Harvard Medical School, Director of the Retina Service at Massachusetts Eye and Ear Infirmary, and Director of the Retina Fellowship at Harvard and Massachusetts Eye and Ear Infirmary.

  • PR Newswire2 months ago

    Aldeyra Therapeutics to Host 2019 Research & Development Day

    LEXINGTON, Mass. , Feb. 12, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve ...

  • GlobeNewswire3 months ago

    Research Report Identifies Cameco, American Equity Investment Life Holding, AG Mortgage Investment Trust, Arena Pharmaceuticals, Mimecast, and Aldeyra Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Jan. 30, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • PR Newswire3 months ago

    Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision

    LEXINGTON, Mass., Jan. 29, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it has acquired Helio Vision, Inc. (Helio Vision), a privately held biotechnology company. The acquisition adds to Aldeyra's pipeline a Phase 3-ready product candidate (ADX-2191, intravitreal methotrexate) for the treatment of proliferative vitreoretinopathy (PVR), a serious sight-threatening condition with no approved treatment.

  • PR Newswire3 months ago

    Aldeyra Therapeutics Announces Promotion of Stephen G. Machatha, Ph.D. to Position of Senior Vice President of Technical Operations

    LEXINGTON, Mass., Jan. 15, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to inventing, developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Stephen G. Machatha, Ph.D. has been promoted to the position of Senior Vice President, Technical Operations, effective immediately. In his new role, Dr. Machatha will lead Chemistry, Manufacturing and Control activities, and develop Aldeyra's commercial supply infrastructure. Dr. Machatha joined Aldeyra in 2016 as Vice President of Chemistry Manufacturing and Controls.

  • PR Newswire4 months ago

    Aldeyra Therapeutics Announces Promotion of David McMullin to Position of Chief Commercial Officer

    LEXINGTON, Mass., Jan. 3, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that David McMullin has been promoted to the position of Chief Commercial Officer, effective immediately. Mr. McMullin joined Aldeyra in May 2018 as Senior Vice President and Head of Corporate Development and Strategy, and has more than 20 years of experience leading commercialization, business development, and strategic planning operations in the biopharmaceutical industry.  Prior to joining Aldeyra, Mr. McMullin was Group Vice President and Head of U.S. Internal Medicine at Shire plc, a $1.4 billion commercial business unit.  Mr. McMullin also ran Global Commercial Operations at Shire Plc and was an in-line Committee member, responsible for commercial performance and execution worldwide.  Prior to his work at Shire, Mr. McMullin held roles of increasing responsibility in corporate strategy, marketing, sales, and operations at Novartis International AG.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of ALDX earnings conference call or presentation 14-Nov-18 1:00pm GMT

    Q3 2018 Aldeyra Therapeutics Inc Earnings Call

  • PR Newswire4 months ago

    Aldeyra Therapeutics Announces Last Patient Dosed in the ALLEVIATE Phase 3 Clinical Trial

    LEXINGTON, Mass., Dec. 20, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that the last patient has completed dosing in the ALLEVIATE Phase 3 clinical trial of topical ocular reproxalap in patients with allergic conjunctivitis. "We look forward to announcing the results of the ALLEVIATE clinical trial in early 2019 as the first of three Phase 3 readouts expected next year," stated Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. "Affecting approximately 20% of the population worldwide, allergic conjunctivitis is a common disease that can cause persistently disturbing symptoms, and is often associated with dry eye disease.